Interleukin-6 upregulates expression of ADAMTS-4 in fibroblast-like synoviocytes from patients with rheumatoid arthritis

International Journal of Rheumatic Diseases

Volumn 15, Issue 1, 2012, Pages 36-44

  Mimata, Yoshikuni ^a   Kamataki, Akihisa ^a   Oikawa, Shinya ^a   Murakami, Kenya ^a   Uzuki, Miwa ^a   Shimamura, Tadashi ^a   Sawai, Takashi ^a  

^a IWATE MEDICAL UNIVERSITY   (Japan)

Author keywords

ADAMTS 4; ADAMTS 5; Fibroblast like synoviocytes; Interleukin 6; Rheumatoid arthritis

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; AGGRECANASE 1; AGGRECANASE 2; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; PARTHENOLIDE;

ARTICLE; CELL ISOLATION; CELL STIMULATION; CONTROLLED STUDY; DOWN REGULATION; FIBROBLAST; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANNUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SYNOVIOCYTE; SYNOVIUM; UPREGULATION;

ADAM PROTEINS; ARTHRITIS, RHEUMATOID; CARTILAGE, ARTICULAR; CELLS, CULTURED; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-6; MAP KINASE KINASE KINASES; PROCOLLAGEN N-ENDOPEPTIDASE; PROTEIN KINASE INHIBITORS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN-6; RECOMBINANT PROTEINS; RNA, MESSENGER; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; SYNOVIAL MEMBRANE; TIME FACTORS; UP-REGULATION;

EID: 84857057096     PISSN: 17561841     EISSN: 1756185X     Source Type: Journal    
DOI: 10.1111/j.1756-185X.2011.01656.x     Document Type: Article

References (45)

1. Pap T, Müller-Ladner U, Gay RE, Gay S (2000) Fibroblast biology. Role of synovial fibroblasts in the pathogenesis of rheumatoid arthritis. Arthritis Res2, 361-7.
2. Takayanagi H, Iizuka H, Juji Tet al. (2000) Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum43, 259-69.
3. Abeles AM, Pillinger MH (2006) The role of the synovial fibroblast in rheumatoid arthritis: cartilage destruction and the regulation of matrix metalloproteinases. Bull NYU Hosp Jt Dis64, 20-4.
4. Goldring MB, Marcu KB (2009) Cartilage homeostasis in health and rheumatic diseases. Arthritis Res Ther11, 224.
5. Nicholson AC, Malik SB, Logsdon JMJr, Van Meir EG (2005) Functional evolution of ADAMTS genes: evidence from analyses of phylogeny and gene organization. BMC Evol Biol5, 11.
6. Kuno K, Kanada N, Nakashima E, Fujiki F, Ichimura F, Matsushima K (1997) Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J Biol Chem272, 556-62.
7. Tortorella MD, Burn TC, Pratta MAet al. (1999) Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science284, 1664-6.
8. Abbaszade I, Liu RQ, Yang Fet al. (1999) Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem274, 23443-50.
9. Kuno K, Okada Y, Kawashima Het al. (2000) ADAMTS-1 cleaves a cartilage proteoglycan, aggrecan. FEBS Lett478, 241-5.
10. Collins-Racie LA, Flannery CR, Zeng Wet al. (2004) ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol23, 219-30.
11. Zeng W, Corcoran C, Collins-Racie LA, Lavallie ER, Morris EA, Flannery CR (2006) Glycosaminoglycan-binding properties and aggrecanase activities of truncated ADAMTSs: comparative analyses with ADAMTS-5, -9, -16 and -18. Biochim Biophys Acta1760, 517-24.
12. Sandy JD, Neame PJ, Boynton RE, Flannery CR (1991) Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain. J Biol Chem266, 8683-5.
13. Lohmander LS, Neame PJ, Sandy JD (1993) The structure of aggrecan fragments in human synovial fluid. Evidence that aggrecanase mediates cartilage degradation in inflammatory joint disease, joint injury, and osteoarthritis. Arthritis Rheum36, 1214-22.
14. Lark MW, Bayne EK, Flanagan Jet al. (1997) Aggrecan degradation in human cartilage. Evidence for both matrix metalloproteinase and aggrecanase activity in normal, osteoarthritic, and rheumatoid joints. J Clin Invest100, 93-106.
15. Vankemmelbeke MN, Holen I, Wilson AGet al. (2001) Expression and activity of ADAMTS-5 in synovium. Eur J Biochem268, 1259-68.
16. Yamanishi Y, Boyle DL, Clark Met al. (2002) Expression and regulation of aggrecanase in arthritis: the role of TGF-beta. J Immunol168, 1405-12.
17. Bau B, Gebhard PM, Haag J, Knorr T, Bartnik E, Aigner T (2002) Relative messenger RNA expression profiling of collagenases and aggrecanases in human articular chondrocytes in vivo and in vitro. Arthritis Rheum46, 2648-57.
18. Naito S, Shiomi T, Okada Aet al. (2007) Expression of ADAMTS4 (aggrecanase-1) in human osteoarthritic cartilage. Pathol Int57, 703-11.
19. Malfait AM, Liu RQ, Ijiri K, Komiya S, Tortorella MD (2002) Inhibition of ADAM-TS4 and ADAM-TS5 prevents aggrecan degradation in osteoarthritic cartilage. J Biol Chem277, 22201-8.
20. Bondeson J, Lauder S, Wainwright Set al. (2007) Adenoviral gene transfer of the endogenous inhibitor IkappaBalpha into human osteoarthritis synovial fibroblasts demonstrates that several matrix metalloproteinases and aggrecanases are nuclear factor-kappaB-dependent. J Rheumatol34, 523-33.
21. Houssiau FA, Devogelaer JP, Van Damme J, de Deuxchaisnes CN, Van Snick J (1988) Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum31, 784-8.
22. Desgeorges A, Gabay C, Silacci Pet al. (1997) Concentrations and origins of soluble interleukin 6 receptor-alpha in serum and synovial fluid. J Rheumatol24, 1510-6.
23. Usón J, Balsa A, Pascual-Salcedo Det al. (1997) Soluble interleukin 6 (IL-6) receptor and IL-6 levels in serum and synovial fluid of patients with different arthropathies. J Rheumatol24, 2069-75.
24. Hashizume M, Hayakawa N, Mihara M (2008) IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. Rheumatology (Oxford)47, 1635-40.
25. Hashizume M, Hayakawa N, Suzuki M, Mihara M (2009) IL-6/sIL-6R trans-signalling, but not TNF-alpha induced angiogenesis in a HUVEC and synovial cell co-culture system. Rheumatol Int29, 1449-54.
26. Legendre F, Bogdanowicz P, Boumediene K, Pujol JP (2005) Role of interleukin 6 (IL-6)/IL-6R-induced signal tranducers and activators of transcription and mitogen-activated protein kinase/extracellular. J Rheumatol32, 1307-16.
27. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G, Schaper F (2003) Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J374, 1-20.
28. Jones SA, Horiuchi S, Topley N, Yamamoto N, Fuller GM (2001) The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J15, 43-58.
29. Nishimoto N, Hashimoto J, Miyasaka Net al. (2007) Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis66, 1162-7.
30. Nishimoto N, Miyasaka N, Yamamoto Ket al. (2009) Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol19, 12-9.
31. Kawakami A, Nakashima T, Sakai Het al. (1999) Regulation of synovial cell apoptosis by proteasome inhibitor. Arthritis Rheum42, 2440-8.
32. Sobota R, Szwed M, Kasza A, Bugno M, Kordula T (2000) Parthenolide inhibits activation of signal transducers and activators of transcription (STATs) induced by cytokines of the IL-6 family. Biochem Biophys Res Commun267, 329-33.
33. Favata MF, Horiuchi KY, Manos EJet al. (1998) Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem273, 18623-32.
34. Case JP, Lafyatis R, Remmers EF, Kumkumian GK, Wilder RL (1989) Transin/stromelysin expression in rheumatoid synovium. A transformation-associated metalloproteinase secreted by phenotypically invasive synoviocytes. Am J Pathol135, 1055-64.
35. Firestein GS, Paine MM (1992) Stromelysin and tissue inhibitor of metalloproteinases gene expression in rheumatoid arthritis synovium. Am J Pathol140, 1309-14.
36. Sawai T, Uzuki M, Harris EDJr, Kurkinnen M, Trelstad RL, Hayashi M (1996) In situ hybridization of stromelysin mRNA in the synovial biopsies from rheumatoid arthritis. Tohoku J Exp Med178, 315-30.
37. Glasson SS, Askew R, Sheppard Bet al. (2004) Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum50, 2547-58.
38. Glasson SS, Askew R, Sheppard Bet al. (2005) Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature434, 644-8.
39. Stanton H, Rogerson FM, East CJet al. (2005) ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature434, 648-52.
40. Fosang AJ, Rogerson FM, East CJ, Stanton H (2008) ADAMTS-5: the story so far. Eur Cell Mater15, 11-26.
41. Axmann R, Böhm C, Krönke G, Zwerina J, Smolen J, Schett G (2009) Inhibition of interleukin-6 receptor directly blocks osteoclast formation in vitro and in vivo. Arthritis Rheum60, 2747-56.
42. Yu H, Pardoll D, Jove R (2009) STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer9, 798-809.
43. Tian SS, Lamb P, Seidel HM, Stein RB, Rosen J (1994) Rapid activation of the STAT3 transcription factor by granulocyte colony-stimulating factor. Blood84, 1760-4.
44. Baumann H, Morella KK, White DWet al. (1996) The full-length leptin receptor has signaling capabilities of interleukin 6-type cytokine receptors. Proc Natl Acad Sci USA93, 8374-8.
45. Hui W, Barksby HE, Young DA, Cawston TE, McKie N, Rowan AD (2005) Oncostatin M in combination with tumour necrosis factor α induces a chondrocyte membrane associated aggrecanase that is distinct from ADAMTS aggrecanase-1 or -2. Ann Rheum Dis64, 1624-32.